var title_f41_35_42544="Marked honeycombing in IPF CT";
var content_f41_35_42544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Marked honeycombing in IPF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Usual interstitial pneumonia pattern with marked honeycombing and traction bronchiectasis in both lower lobes along with an absence of ground glass changes. The peripheral regions of the lower lobes and middle lobe are typically involved, initially sparing the central parts of the lower lobes.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42544=[""].join("\n");
var outline_f41_35_42544=null;
var title_f41_35_42545="PCLBCL-LT clinical presentation I";
var content_f41_35_42545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous diffuse large B-cell lymphoma, leg type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with a primary cutaneous diffuse large B-cell lymphoma, leg type presenting with localized skin tumors on the left leg. Most patients present with red or bluish nodules or tumors on one or both legs, preferentially the lower legs. Ten to 15 percent will develop outside of the lower extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42545=[""].join("\n");
var outline_f41_35_42545=null;
var title_f41_35_42546="Pulm AVM CT IV";
var content_f41_35_42546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with Weber-Osler-Rendu syndrome presents with bilateral AVM's",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan demonstrates a small left lower lobe AVM.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42546=[""].join("\n");
var outline_f41_35_42546=null;
var title_f41_35_42547="Budesonide (nasal): Pediatric drug information";
var content_f41_35_42547=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Budesonide (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?18/55/19317?source=see_link\">",
"    see \"Budesonide (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/59/8116?source=see_link\">",
"    see \"Budesonide (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7998588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rhinocort Aqua&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7998589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mylan-Budesonide AQ;",
"     </li>",
"     <li>",
"      Rhinocort&reg; Aqua&reg;;",
"     </li>",
"     <li>",
"      Rhinocort&reg; Turbuhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10586104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Intranasal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10586164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/55/19317?source=see_link\">",
"      see \"Budesonide (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal:",
"     <b>",
"      Seasonal or perennial rhinitis:",
"     </b>",
"     Children &ge;6 years and Adults: Rhinocort&reg; Aqua&reg; (32 mcg/spray): Initial: 2 sprays (1 spray/nostril) once daily (64 mcg/day); dose may be increased if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum daily dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;12 years: 4 sprays (2 sprays/nostril) once daily (128 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults: 8 sprays (4 sprays/nostril) once daily (256 mcg/day)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7998763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinocort Aqua&reg;: 32 mcg/inhalation (8.6 g) [120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7998590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10586165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clear nasal passage by blowing nose prior to use; shake container gently before use. Prime before first use; discard after 120 sprays. Do not spray into eyes or mouth.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10586124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store with valve up at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Avoid storage in high humidity; do not store or use by heat or open flame.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10586105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of seasonal or perennial allergic rhinitis (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7998639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reaction severity varies by dose and duration; not all adverse reactions have been reported with each dosage form.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, epistaxis, nasal congestion, nasal irritation, pharyngitis, throat irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anosmia, growth suppression, hypersensitivity reactions (immediate and delayed [includes rash, contact dermatitis, angioedema, bronchospasm]), nasal septum perforation, pharyngeal disorders (irritation, throat pain, itchy throat)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10586106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended dosages; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercorticism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth). Use budesonide with extreme caution in patients with respiratory tuberculosis; untreated bacterial, fungal, systemic viral or parasitic infections; or ocular herpes simplex. Localized",
"     <i>",
"      Candida",
"     </i>",
"     infections of the nose and pharynx have been reported rarely; interruption of therapy may be necessary while antifungal therapy is employed. Corticosteroids impair wound healing; avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma; allow healing to occur before use. Use of nasal budesonide in place of systemic corticosteroids may unmask allergies (eg, eczema, rhinitis) that were previously controlled by the systemic corticosteroids. Rare cases of immediate hypersensitivity reactions, nasal septum perforation, increased IOP, glaucoma, or cataracts may occur with intranasal corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13365158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HPA suppression or hypercorticism (Cushing's syndrome) may occur with use of higher than recommended doses or at typical doses in susceptible patients. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use, with stress, or when converting from systemic to topical corticosteroid therapy; withdrawal or discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Epistaxis may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potent inhibitors of cytochrome P450 isoenzyme CYP3A4 (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin) may significantly increase budesonide serum concentrations and result in systemic corticosteroid effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Budesonide (Nasal). Management: Concurrent use of telaprevir with inhaled budesonide is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7998631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7998632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Studies of pregnant women using intranasal budesonide have not demonstrated an increased risk of abnormalities. Intranasal corticosteroids may be used in the treatment of rhinitis during pregnancy; budesonide is preferred (Wallace,  2008)",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10586166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor growth in pediatric patients; check mucous membranes for signs of fungal infection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10586125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10586126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical effects are due to direct local effect, rather than systemic absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration after discontinuation: Several days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10586127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 34% of dose delivered reaches systemic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 85% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively metabolized by the liver via cytochrome P450 CYP3A isoenzyme to 2 major metabolites: 16&alpha;-hydroxyprednisolone and 6&beta;-hydroxybudesonide; both are &lt;1% as active as parent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 10-14 years: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 2-3.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 60% to 66% of dose renally excreted as metabolites; no unchanged drug found in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 4-6 years: 0.5 L/minute (~50% greater than healthy adults after weight adjustment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 0.9-1.8 L/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10586167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/59/8116?source=see_link\">",
"      see \"Budesonide (nasal): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Full response to this medication may not be seen for 2-5 weeks. Use regularly. Do not stop treatment, even if feeling better. Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval. Avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay. Report sore mouth or mouth lesions, persistent headache, or nosebleeds to physician; carefully read and follow the patient instructions for use leaflet that accompanies the product.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15945 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42547=[""].join("\n");
var outline_f41_35_42547=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998588\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998589\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586104\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586164\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998763\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998590\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586165\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586124\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586105\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998639\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586106\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365158\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082584\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082585\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998631\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998632\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586166\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586125\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586126\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586127\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586167\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15945\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15945|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/55/19317?source=related_link\">",
"      Budesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/59/8116?source=related_link\">",
"      Budesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/39/10873?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/45/25303?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/36/21064?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_35_42548="Choline magnesium trisalicylate: Patient drug information";
var content_f41_35_42548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Choline magnesium trisalicylate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/43/42677?source=see_link\">",
"     see \"Choline magnesium trisalicylate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/45/8917?source=see_link\">",
"     see \"Choline magnesium trisalicylate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to choline magnesium trisalicylate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703718",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark, tarry-black stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills. Mix liquid with juice before drinking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Arthritis:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12111 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42548=[""].join("\n");
var outline_f41_35_42548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030513\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030512\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030517\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030518\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030520\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030515\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030516\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030521\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030522\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/43/42677?source=related_link\">",
"      Choline magnesium trisalicylate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/45/8917?source=related_link\">",
"      Choline magnesium trisalicylate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_35_42549="Eye anatomy in cross section";
var content_f41_35_42549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Eye anatomy in cross section",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 551px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42549=[""].join("\n");
var outline_f41_35_42549=null;
var title_f41_35_42550="Rtxn pocket cholesteatoma";
var content_f41_35_42550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Treatment of early retraction pocket cholesteatoma with middle ear ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Collapse of the drum with posterosuperior deep retraction pocket. Panel B) Retraction pocket after tube placement. Panel C) Reduction of the retraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42550=[""].join("\n");
var outline_f41_35_42550=null;
var title_f41_35_42551="Group A streptococcal (Streptococcus pyogenes) bacteremia in adults";
var content_f41_35_42551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Group A streptococcal (Streptococcus pyogenes) bacteremia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42551/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42551/contributors\">",
"     Dennis L Stevens, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42551/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42551/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42551/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42551/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/35/42551/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group A streptococcus (GAS, eg, Streptococcus pyogenes) is an aerobic gram-positive coccus that causes pharyngitis and a variety of cutaneous infections (eg, pyoderma, erysipelas, cellulitis), invasive infections, and other complications such as acute rheumatic fever, acute glomerulonephritis, and toxic shock syndrome (TSS). Invasive GAS infections are defined as bacteremia, pneumonia, or any other infection associated with the isolation of GAS from a normally sterile body site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/1\">",
"     1",
"    </a>",
"    ]. Invasive infections also include necrotizing fasciitis and spontaneous gangrenous myositis.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, treatment, and prognosis of GAS bacteremia in adults will be reviewed here. Issues related to GAS bacteremia in children and to other GAS infections (TSS and invasive disease) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3944?source=see_link\">",
"     \"Group A streptococcal (Streptococcus pyogenes) bacteremia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8519?source=see_link\">",
"     \"Treatment of streptococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;GAS bacteremia is usually secondary to a primary site of infection, which most commonly occurs in the skin and soft tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The frequency with which it occurs was evaluated in a review of blood cultures from a single institution in Israel over a 10-year period (1993-2002) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/4\">",
"     4",
"    </a>",
"    ]. GAS accounted for 0.6 percent of cases of bacteremia in adults, and GAS bacteremia was diagnosed in 1 in 500 hospitalizations.",
"   </p>",
"   <p>",
"    An increasing prevalence of severe GAS infections occurred between 1985 and 1994, predominantly in North America and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. A study in Norway found a threefold increase in the occurrence of GAS bacteremia from 1987 to 1988 compared with previous years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/6\">",
"     6",
"    </a>",
"    ]. The greatest increase (six- to eightfold) was in adolescents and in adults between the ages of 30 and 50.",
"   </p>",
"   <p>",
"    Since that time, attack rates have been stable. In the United States, an average of 1168 cases (range 1077 to 1288) of invasive GAS infection were reported to the Active Bacterial Core Surveillance at the Centers for Disease Control and Prevention (CDC) each year from 2005 to 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. The incidence is probably much higher since passive reporting underestimates the disease. The CDC estimates that approximately 12,500 cases of invasive GAS disease and 1250 deaths occurred nationally during 2010. Among individuals &lt;65 years of age, the age-specific incidence of invasive GAS disease is greatest in those &le;1 year (5.2 to 5.8 cases per 100,000 in 2010).",
"   </p>",
"   <p>",
"    The factors responsible for the marked increase in prevalence of severe GAS infections between 1985 and 1994 were not well defined. Interest focused on changes in the strains of GAS causing invasive infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/2,3,7,8,15\">",
"     2,3,7,8,15",
"    </a>",
"    ]. It has been suggested that alterations in the distribution of M-types causing infection, together with an increasing prevalence of toxin-producing strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/7,8,15\">",
"     7,8,15",
"    </a>",
"    ], could be responsible. Overall, the incidence of bacteremia in patients with streptococcal toxic shock syndrome is 50 to 60 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In favor of this theory is the observation that a finite number of M-types of GAS (1, 3, 4, 6, and 28) cause about 50 percent of invasive infections; the remaining 50 percent are caused by a variety of different strains, including non-typeable strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/1-3,5,7,15,16\">",
"     1-3,5,7,15,16",
"    </a>",
"    ]. In addition, all GAS strains isolated from invasive cases produce a toxin called NADase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/16\">",
"     16",
"    </a>",
"    ]. All M-1 strains (the most common isolate from bacteremic cases since 1985) produce this toxin, whereas strains of M-1 isolated prior to 1985 (before the increase in prevalence of invasive GAS infections) did not produce the NADase toxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clusters of severe GAS infections have been observed in long term care facilities. In 2008, a cluster of 11 severe GAS infections was reported in a long-term acute care hospital in New Mexico [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/17\">",
"     17",
"    </a>",
"    ], and between 2009 and 2010 a cluster of 23 cases (including 13 invasive infections) occurred in a skilled nursing facility in Pennsylvania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/18\">",
"     18",
"    </a>",
"    ]. Lapses in infection control practices likely allowed ongoing transmission, highlighting the importance of adherence to careful control measures as well as case cohorting in the setting of GAS infection.",
"   </p>",
"   <p>",
"    Among 664 cases of invasive GAS infection identified prospectively in France between 2006 and 2007, bacteremia was observed in 70 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/19\">",
"     19",
"    </a>",
"    ]. The median age was 55 years and the incidence was 3.1 per 100,000; rates were highest in children &lt;5 years (5.7 per 100,000) and adults &ge;70 (8.4 per 100,000). Skin and soft tissue infections accounted for 30 percent of cases; toxic shock was observed in 20 percent of cases. In-hospital mortality was 43 percent among patients presenting with toxic shock (14 percent overall). Factors independently associated with mortality on multivariate analysis included age &ge;50, preexisting hepatic disease, toxic shock syndrome, bacteremia without an identified focus, and infection caused by an M-1 strain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal bacteremia has traditionally been most common in the very young and elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/20-28\">",
"     20-28",
"    </a>",
"    ]. Most series now find that persons of all ages may be afflicted with GAS and most are not immunosuppressed.",
"   </p>",
"   <p>",
"    The risk factors for GAS bacteremia vary with age.",
"   </p>",
"   <p>",
"    Among children, predisposing factors reported from population-based and clinical reports include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/1,2,7,29-31\">",
"     1,2,7,29-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Burns",
"     </li>",
"     <li>",
"      Varicella virus infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Malignant neoplasm",
"     </li>",
"     <li>",
"      Immunosuppression",
"     </li>",
"     <li>",
"      Age less than two years",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients aged 14 to 40, GAS bacteremia has generally been rare in the United States and Europe. GAS among this age group tends to occur in the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/20,25,28,32,33\">",
"     20,25,28,32,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Puerperal sepsis, common in the distant past [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/20\">",
"       20",
"      </a>",
"      ], rare in the recent past, but reemerging during the last 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intravenous drug use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/25,28,32,35\">",
"       25,28,32,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HIV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/33,35\">",
"       33,35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective evaluation of 100 patients with GAS bacteremia, 62 were intravenous drug users (IDUs); all but one had an obvious cutaneous portal of entry related to the injection of illicit drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/32\">",
"     32",
"    </a>",
"    ]. Among the 38 patients who were not IDUs, 24 had an underlying disease and 12 were immunosuppressed, five due to HIV infection. Overall, GAS bacteremia was 39 times more common in HIV-infected patients than in those not infected with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/28\">",
"     28",
"    </a>",
"    ]. Population based studies of invasive GAS infections have identified HIV as a predisposing factor in 4 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/33\">",
"     33",
"    </a>",
"    ]. In western Canada, increased incidence of invasive GAS infections among homeless individuals was reported, some of whom were IDUs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/36\">",
"     36",
"    </a>",
"    ]. The responsible strain, an M-59 type of GAS, has been rarely reported over the last several decades.",
"   </p>",
"   <p>",
"    However, in a study of invasive GAS infection in the Rocky Mountain area, only 2 of the 20 patients were IDUs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/15\">",
"     15",
"    </a>",
"    ]. There was a marked increase in the prevalence of GAS bacteremia in younger adults in association with other manifestations of severe GAS infection including necrotizing fasciitis, myositis, and shock.",
"   </p>",
"   <p>",
"    Among patients aged &gt;40 years, the risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Burns [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Surgical procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nonpenetrating trauma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nosocomial transmission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/2,35,39\">",
"       2,35,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Peripheral vascular disease",
"     </li>",
"     <li>",
"      Malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/35,39,40\">",
"       35,39,40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Corticosteroid use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/2,35\">",
"       2,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immunosuppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cardiac disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SOURCES OF BACTEREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;GAS bacteremia may arise in patients with infections of the pharynx, lung, skin, and soft tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia associated with GAS pharyngitis is uncommon; even during scarlet fever, bacteremia occurs in only 0.3 percent of febrile patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/41\">",
"     41",
"    </a>",
"    ]. Nevertheless, among patients with scarlet fever, the pharynx is the most common source of bloodstream GAS. Bacteremic patients frequently have additional complications such as extension of infection into the sinuses, peritonsillar tissue, or mastoids (septic scarlet fever or scarlet fever anginosa).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the lower respiratory tract is the least common source of bacteremia, in adults with GAS pneumonia, the incidence of bacteremia is 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/30\">",
"     30",
"    </a>",
"    ]. Group A streptococcal pneumonia has been a complication of both the 1918 influenza pandemic as well as the 2009-2010 H1N1 influenza epidemic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Skin and soft tissue infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The source of GAS bacteremia is almost invariably the skin in adults (particularly the elderly) and IDUs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. Cellulitis and erysipelas are the most common associations. As an example, epidemics of GAS bacteremia associated with soft tissue infection among the institutionalized elderly have been reported for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/31,42\">",
"     31,42",
"    </a>",
"    ]. Affected patients may also have other signs of invasive GAS infection, such as necrotizing fasciitis or myonecrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/15\">",
"     15",
"    </a>",
"    ]. A prospective-retrospective survey of invasive GAS soft-tissue infections in IDUs during the time period between January 1998 and December 2003 identified 44 cases of invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/43\">",
"     43",
"    </a>",
"    ]. Bacteremia occurred in 27 of 44 (61 percent) cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with burns and varicella virus infection are particularly at risk for GAS bacteremia. In a study of over 2500 children with varicella, GAS bacteremia was demonstrated in approximately 0.5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/41\">",
"     41",
"    </a>",
"    ]. A retrospective review of children with documented GAS bacteremia from January 1977 through December 1993 found that 50 percent of new cases of invasive GAS infection were associated with varicella infection; a common finding was the presence of fever on or beyond the fourth day of the exanthem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/44\">",
"     44",
"    </a>",
"    ]. A retrospective series of 131 patients (60 percent adults) with invasive GAS infections in North Carolina, found that 11 percent had varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of GAS bacteremia include those of the primary site of infection and of the bacteremia. Deep soft tissue infections, such as myonecrosis or necrotizing fasciitis, and postpartum infection (child bed fever) are frequently associated with bacteremia, shock, and organ failure.",
"   </p>",
"   <p>",
"    With postpartum infection (group A streptococcal endometritis), increasing abdominal pain may be the best clinical clue to possible superimposed infection although abdominal discomfort is expected for 24 to 48 hours following either vaginal delivery or cesarean section. As with meningococcemia, petechiae, ecchymoses, and digital embolization may occur with subsequent evidence of thrombocytopenia and disseminated intravascular coagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GAS bacteremia in injection drug users (IDU) appears to have a less aggressive course than in non-IDU patients. This was illustrated in a prospective study of 100 patients with GAS bacteremia (62 patients with IDU) that compared clinical findings in the IDU versus non-IDU groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/32\">",
"     32",
"    </a>",
"    ]. GAS bacteremia in IDU patients was associated with a longer time of evolution before diagnosis (8.8 versus 4.3 days) and a lower frequency of septic shock (3 versus 29 percent) and mortality (5 versus 29 percent) than in non-IDU patients.",
"   </p>",
"   <p>",
"    GAS bacteremia associated with the early onset of shock and organ failure fits the case definition of streptococcal toxic shock syndrome. Affected patients typically develop renal failure, acute respiratory distress syndrome, hepatic dysfunction, and a diffuse capillary leak syndrome; the mortality rate ranges from 30 to 70 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of a patient with GAS bacteremia most commonly requires a team of clinicians including surgeons and infectious disease and critical care specialists. Treatment includes management of the complications of sepsis, aggressive surgical debridement if a site of infection is identified, and antibiotics for the underlying infection. In the prospective-retrospective survey of invasive GAS soft-tissue infections in IDUs noted above, surgery was required in 18 patients (41 percent), although treatment was successful in all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8519?source=see_link\">",
"     \"Treatment of streptococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GAS remains exquisitely susceptible to beta-lactam antibiotics. However, clinical failures of penicillin therapy for streptococcal infections do occur. Penicillin fails to eradicate bacteria from the pharynx of patients with documented streptococcal pharyngitis in 5 to 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/45\">",
"     45",
"    </a>",
"    ]. The failure rate may be higher in patients with invasive infections in which a larger number of organisms may be present.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    may be more effective in these settings in part because its efficacy is not affected by inoculum size or stage of growth and because it suppresses toxin production. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8519?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of streptococcal toxic shock syndrome\", section on 'Clindamycin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive studies, which establish the most effective antibiotic regimen in treating GAS bacteremia, are not available. Animal models, as well as a retrospective review, favor combination treatment with a beta-lactam plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. In the retrospective review, the outcome of treatment of 56 children with invasive GAS infections found that a favorable outcome was statistically more likely in patients who received a protein synthesis-inhibiting antibiotic (eg, clindamycin) compared with those who received only a cell wall-inhibiting antibiotic (eg, beta-lactams) (83 versus 14 percent with beta-lactams had a favorable outcome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend combined treatment for GAS bacteremia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (4 million units intravenously every four hours in patients with normal renal function) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (900 mg intravenously every eight hours). In vitro there is no additive, synergistic, or antagonistic effects of penicillin when added to clindamycin. Penicillin is added to clindamycin primarily to cover the patient in the rare event that the organism is resistant to clindamycin; this occurs in less than 1 percent of isolates in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is important to tailor therapy to antibiotic susceptibilities. An increasing number of GAS isolates with constitutive or inducible resistance to macrolide-lincosamide-streptogramin B (MLS) antibiotics, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , has been identified in Europe and the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Retrospective review of invasive GAS disease in Hawaii (2005 to 2007) identified 12 erythromycin- and clindamycin-resistant emm 90.4b GAS isolates that had identical pulse gel electrophoretic patterns, suggesting clonal spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical studies addressing the optimal duration of antibiotic therapy in GAS bacteremia. We recommend that the duration of antibiotic therapy be individualized. Patients are treated for a minimum of 14 days. However, if a serious soft tissue infection (eg, necrotizing fasciitis) is the source of the bacteremia, than the length of therapy depends on the clinical response of the soft tissue infection to antibiotic treatment. Therapy is usually continued for 14 days from the last positive culture obtained during surgical debridement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the use of intravenous immune globulin in patients with invasive GAS infections who develop signs of shock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8519?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of streptococcal toxic shock syndrome\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GAS bacteremia remains a serious infection. Among reviews on invasive GAS infections (not solely GAS bacteremia) published after 1985, the mortality rate has ranged from 25 to 48 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/6,15,26-28\">",
"     6,15,26-28",
"    </a>",
"    ]. Among those patients with invasive GAS infections who develop shock, mortality is higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/15,26\">",
"     15,26",
"    </a>",
"    ]. For example, shock is the most important predictor of mortality (79 versus 16 percent in those without shock in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42551/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33569?source=see_link\">",
"       \"Patient information: Sepsis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptococcal bacteremia has traditionally been most common in the very young and elderly. Most series now find that persons of all ages may be afflicted with GAS and most are not immunosuppressed. The risk factors for GAS bacteremia vary with age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GAS bacteremia is usually secondary to a primary site of infection, including infections of the pharynx, lung, skin, and soft tissues. Most commonly, the primary infection occurs in the skin and soft tissues. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sources of bacteremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of GAS bacteremia include those of the primary site of infection and of the bacteremia. Bacteremia may be complicated by shock and organ failure. However, the clinical course of GAS bacteremia in IDU patients appears to be less aggressive than in non-IVDU patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal management of a patient with GAS bacteremia includes management of the complications of sepsis, aggressive surgical debridement if a site of infection is identified, and antibiotics for the underlying infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strong observational evidence suggests that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      is more effective than penicillin for the treatment of GAS bacteremia. However, resistance to clindamycin is increasing in some geographic regions. We recommend treatment with clindamycin (900 mg IV every eight hours) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (4 million units IV every four hours) for GAS bacteremia (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of antibiotic therapy for GAS bacteremia should be individualized. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GAS bacteremia remains a serious infection. The mortality rate for invasive GAS infections has ranged from 25 to 48 percent, with higher mortality among those patients who develop shock. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/1\">",
"      Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/2\">",
"      Kiska DL, Thiede B, Caracciolo J, et al. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis 1997; 176:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/3\">",
"      Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993; 16:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/4\">",
"      Megged O, Yinnon AM, Raveh D, et al. Group A streptococcus bacteraemia: comparison of adults and children in a single medical centre. Clin Microbiol Infect 2006; 12:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/5\">",
"      Gaworzewska E, Colman G. Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol Infect 1988; 100:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/6\">",
"      Martin PR, H&oslash;iby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990; 22:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/7\">",
"      Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990; 336:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/8\">",
"      Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992; 166:31.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs). ABCs Report: group A Streptococcus, 2005. file://www.cdc.gov/abcs/reports-findings/survreports/gas05.html (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs). ABCs Report: group A Streptococcus, 2006. file://www.cdc.gov/abcs/reports-findings/survreports/gas06.html (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs). ABCs Report: group A Streptococcus, 2007. file://www.cdc.gov/abcs/reports-findings/survreports/gas07.html (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs). ABCs Report: group A Streptococcus, 2008. file://www.cdc.gov/abcs/reports-findings/survreports/gas08.html (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs). ABCs Report: group A Streptococcus, 2009. file://www.cdc.gov/abcs/reports-findings/survreports/gas09.html (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and prevention. Active Bacterial Core Surveillance (ABCs). ABCs Report: group A Streptococcus, 2010 file://www.cdc.gov/abcs/reports-findings/survreports/gas10.html (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/15\">",
"      Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/16\">",
"      Stevens DL, Salmi DB, McIndoo ER, Bryant AE. Molecular epidemiology of nga and NAD glycohydrolase/ADP-ribosyltransferase activity among Streptococcus pyogenes causing streptococcal toxic shock syndrome. J Infect Dis 2000; 182:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/17\">",
"      Deutscher M, Schillie S, Gould C, et al. Investigation of a group A streptococcal outbreak among residents of a long-term acute care hospital. Clin Infect Dis 2011; 52:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Invasive group A streptococcus in a skilled nursing facility--Pennsylvania, 2009-2010. MMWR Morb Mortal Wkly Rep 2011; 60:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/19\">",
"      Lepoutre A, Doloy A, Bidet P, et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol 2011; 49:4094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/20\">",
"      Keefer CS, Ingelfinger FJ, Spink WW. Significance of hemolytic streptococcic bacteremia; A study of two hundred and forty-six patients. Arch Intern Med 1937; 60:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/21\">",
"      Ispahani P, Donald FE, Aveline AJ. Streptococcus pyogenes bacteraemia: an old enemy subdued, but not defeated. J Infect 1988; 16:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/22\">",
"      Henkel JS, Armstrong D, Blevins A, Moody MD. Group A beta-hemolytic Streptococcus bacteremia in a cancer hospital. JAMA 1970; 211:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/23\">",
"      Hable KA, Horstmeier C, Wold AD, Washington JA 2nd. Group A -hemolytic streptococcemia. Bacteriologic and clinical study of 44 cases. Mayo Clin Proc 1973; 48:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/24\">",
"      Trence DL, Khan MY, Gerding DN. Beta-hemolytic streptococcal bacteremia in adults: association with cold weather in Minnesota. Minn Med 1981; 64:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/25\">",
"      Barg NL, Kish MA, Kauffman CA, Supena RB. Group A streptococcal bacteremia in intravenous drug abusers. Am J Med 1985; 78:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/26\">",
"      Francis J, Warren RE. Streptococcus pyogenes bacteraemia in Cambridge--a review of 67 episodes. Q J Med 1988; 68:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/27\">",
"      Barnham M. Invasive streptococcal infections in the era before the acquired immune deficiency syndrome: a 10 years' compilation of patients with streptococcal bacteraemia in North Yorkshire. J Infect 1989; 18:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/28\">",
"      Braunstein H. Characteristics of group A streptococcal bacteremia in patients at the San Bernardino County Medical Center. Rev Infect Dis 1991; 13:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/29\">",
"      Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002). J Clin Microbiol 2005; 43:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/30\">",
"      Muller MP, Low DE, Green KA, et al. Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Arch Intern Med 2003; 163:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/31\">",
"      Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997; 103:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/32\">",
"      Bernaldo de Quir&oacute;s JC, Moreno S, Cercenado E, et al. Group A streptococcal bacteremia. A 10-year prospective study. Medicine (Baltimore) 1997; 76:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/33\">",
"      Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996; 335:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/34\">",
"      Ejlertsen T, Prag J, Pettersson E, Holmskov A. A 7-month outbreak of relapsing postpartum group A streptococcal infections linked to a nurse with atopic dermatitis. Scand J Infect Dis 2001; 33:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/35\">",
"      Factor SH, Levine OS, Schwartz B, et al. Invasive group A streptococcal disease: risk factors for adults. Emerg Infect Dis 2003; 9:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/36\">",
"      Tyrrell GJ, Lovgren M, St Jean T, et al. Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada. Clin Infect Dis 2010; 51:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/37\">",
"      Nielsen HU, Kolmos HJ, Frimodt-M&oslash;ller N. Beta-hemolytic streptococcal bacteremia: a review of 241 cases. Scand J Infect Dis 2002; 34:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/38\">",
"      Daneman N, Green KA, Low DE, et al. Surveillance for hospital outbreaks of invasive group a streptococcal infections in Ontario, Canada, 1992 to 2000. Ann Intern Med 2007; 147:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/39\">",
"      Ben-Abraham R, Keller N, Vered R, et al. Invasive group A streptococcal infections in a large tertiary center: epidemiology, characteristics and outcome. Infection 2002; 30:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/40\">",
"      Hollm-Delgado MG, Allard R, Pilon PA. Invasive group A streptococcal infections, clinical manifestations and their predictors, Montreal, 1995-2001. Emerg Infect Dis 2005; 11:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/41\">",
"      Bullowa, JGM, Wishik, SM. Complications of varicella I. Their occurrence among 2,534 patients. Am J Dis Child 1935; 49:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/42\">",
"      Kaplan EL, Johnson DR, Kuritsky JN. Rectal colonization by group B beta-hemolytic streptococci in a geriatric population. J Infect Dis 1983; 148:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/43\">",
"      Sierra JM, S&aacute;nchez F, Castro P, et al. Group A streptococcal infections in injection drug users in Barcelona, Spain: epidemiologic, clinical, and microbiologic analysis of 3 clusters of cases from 2000 to 2003. Medicine (Baltimore) 2006; 85:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/44\">",
"      Doctor A, Harper MB, Fleisher GR. Group A beta-hemolytic streptococcal bacteremia: historical overview, changing incidence, and recent association with varicella. Pediatrics 1995; 96:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/45\">",
"      Gastanaduy AS, Kaplan EL, Huwe BB, et al. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet 1980; 2:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/46\">",
"      Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/47\">",
"      Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: New concepts in antibiotic treatment. Int J Antimicrob Agents 1994; 4:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/48\">",
"      Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/49\">",
"      Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/50\">",
"      Gooskens J, Neeling AJ, Willems RJ, et al. Streptococcal toxic shock syndrome by an iMLS resistant M type 77 Streptococcus pyogenes in the Netherlands. Scand J Infect Dis 2005; 37:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42551/abstract/51\">",
"      Chen I, Kaufisi P, Erdem G. Emergence of erythromycin- and clindamycin-resistant Streptococcus pyogenes emm 90 strains in Hawaii. J Clin Microbiol 2011; 49:439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3173 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42551=[""].join("\n");
var outline_f41_35_42551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SOURCES OF BACTEREMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Skin and soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3944?source=related_link\">",
"      Group A streptococcal (Streptococcus pyogenes) bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8519?source=related_link\">",
"      Treatment of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_35_42552="Pathobiology and staging of small cell carcinoma of the lung";
var content_f41_35_42552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathobiology and staging of small cell carcinoma of the lung",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42552/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42552/contributors\">",
"     Anthony Elias, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42552/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42552/contributors\">",
"     Arthur T Skarin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42552/contributors\">",
"     Andrew Nicholson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42552/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/35/42552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell lung cancer (SCLC) is distinguished from non-small cell lung cancer (NSCLC) by its rapid doubling time, high growth fraction, and the early development of widespread metastases. Although considered highly responsive to chemotherapy and radiotherapy, SCLC usually relapses and becomes refractory to treatment within one to two years.",
"   </p>",
"   <p>",
"    The epidemiology, pathology, clinical presentation, staging, and prognostic factors of SCLC will be reviewed here. The treatment of SCLC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=see_link\">",
"     \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCLC occurs almost exclusively in smokers and appears to be most common in heavy smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of lung cancer in the United States that is classified as SCLC has steadily decreased. This was illustrated by an analysis of the Surveillance, Epidemiology and End Results (SEER) database, in which the proportion of SCLC declined from 17 percent in 1986 to 13 percent in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/2\">",
"     2",
"    </a>",
"    ]. This overall decrease in incidence was accompanied by an increase in the percentage of cases of SCLC arising in women (28 percent in 1973 versus 50 percent in 2002).",
"   </p>",
"   <p>",
"    These epidemiologic changes may be due to differences in smoking patterns (eg, decreased in men) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, changes in the pathologic criteria for SCLC may have led to a classification of some cases as having large cell neuroendocrine carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Classification of SCLC'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classification of SCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic classification of SCLC has evolved over several decades. Initially, the World Health Organization (WHO) classified SCLC into the three histologic subtypes (oat cell, intermediate cell type, and combined [SCLC with non-small cell (usually squamous cell or adenocarcinoma) component]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/3\">",
"     3",
"    </a>",
"    ]. This classification system has undergone progressive revisions that attempted to correlate histopathologic observations with clinical behavior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=see_link\">",
"     \"Pathology of lung malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathology of lung malignancies\", section on 'Small cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2004 World Health Organization (WHO) classification of lung tumors eliminated intermediate cell carcinoma and added a new category of large cell neuroendocrine carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/4\">",
"     4",
"    </a>",
"    ]. In 2011, a multidisciplinary expert panel representing the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) proposed a major revision that updated the classification of adenocarcinomas of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/5\">",
"     5",
"    </a>",
"    ]. The WHO and 2011 proposed classification system are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef74747 \" href=\"mobipreview.htm?31/11/31933\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The 2004 WHO classification system recognizes the neuroendocrine origin of carcinoid tumors (",
"    <a class=\"graphic graphic_table graphicRef50502 \" href=\"mobipreview.htm?13/32/13836\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small cell carcinoma (SCLC), classical variant",
"     </li>",
"     <li>",
"      Combined SCLC, consisting predominantly of SCLC with some areas of NSCLC",
"     </li>",
"     <li>",
"      Large cell neuroendocrine cancer, which is distinct from SCLC",
"     </li>",
"     <li>",
"      Typical carcinoid",
"     </li>",
"     <li>",
"      Atypical carcinoid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large cell neuroendocrine cancer appears to have a biologic behavior that is similar to SCLC, which is supported by their gene expression profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=see_link&amp;anchor=H24#H24\">",
"     \"Pathology of lung malignancies\", section on 'Large cell neuroendocrine carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of SCLC is based primarily upon light microscopy. Small cell carcinoma is characterized by small \"blue\" malignant cells about twice the size of lymphocytes. The cytoplasm is sparse, and nuclear features include finely dispersed chromatin without distinct nucleoli. In contrast, the cells of large cell neuroendocrine carcinoma are distinguished by the presence of prominent nucleoli, a more granular chromatin pattern, and variable amounts of cytoplasm. Mitotic rates are high, and necrosis of individual tumor cells is common. Nuclear molding is considered characteristic in well-preserved specimens, although a nondiagnostic \"crush\" artifact is more frequently observed. The neoplastic cells are typically arranged in clusters, sheets, or trabeculae, separated by a delicate fibrovascular stroma.",
"   </p>",
"   <p>",
"    In the combined cell subtype, SCLC coexists with squamous cell carcinoma, adenocarcinoma, large cell carcinoma, or rarely spindle cell carcinoma. If SCLC coexists with large cell components, at least 10 percent of each component should be present. For other non-small cell elements, the presence of any amount indicates classification as &ldquo;combined&rdquo;. While coexistence with another cell type of carcinoma is rarely detected in untreated specimens, up to 30 percent of autopsies with SCLC demonstrate areas of differentiation into non-small cell carcinoma. This finding has led to the hypothesis that pulmonary carcinogenesis occurs in a pluripotent stem cell capable of differentiation along several pathways.",
"   </p>",
"   <p>",
"    In the combined cell subtype, metastatic disease usually contains predominantly SCLC even if the SCLC element is low. Therefore treatment for patients with the combined subtype that appropriate for SCLC. For patients with stage I or II disease, surgical resection should be considered.",
"   </p>",
"   <p>",
"    The prognostic significance of the combined SCLC variant is unclear. In some reports, the combined variant has been more resistant to treatment and had a short survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/9\">",
"     9",
"    </a>",
"    ]. However, other reports suggest a more favorable prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eight SCLC antigen clusters have been identified by segregation analysis and divided into three groups: neural, epithelial, and neuroendocrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of their epithelial cellular origin, virtually all SCLCs are immunoreactive for keratin and epithelial membrane antigen.",
"     </li>",
"     <li>",
"      Neuroendocrine and neural differentiation result in the expression of dopa decarboxylase, calcitonin, neuron-specific enolase, chromogranin A, CD56 (neural cell adhesion molecule [NCAM]), gastrin releasing peptide (GRP), and insulin-like growth factor-I (IGF-I). One or more markers of neuroendocrine differentiation can be found in approximately 75 percent of SCLCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/13\">",
"       13",
"      </a>",
"      ]. In contrast to the large cell neuroendocrine carcinoma, the immunohistochemical demonstration of neuroendocrine differentiation is not a prerequisite for the diagnosis of small cell carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasional patients can produce autoantibodies that crossreact with both SCLC cells and the central nervous system or the neuromuscular junction. These autoantibodies can cause cerebellar degenerative syndromes or the Lambert Eaton myasthenic syndrome. SCLC is the most common malignancy associated with neurologic paraneoplastic syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2744?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of Lambert-Eaton myasthenic syndrome\", section on 'Evaluation for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCLC cells can also produce a number of polypeptide hormones, including ACTH and vasopressin (antidiuretic hormone), resulting in various paraneoplastic and ectopic hormonal syndromes (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    IGF-I and GRP may also participate in autocrine and paracrine loops to enhance the growth of SCLC cells. In addition to overexpression of these growth factors, the enzyme which inactivates these small polypeptide hormones, neural endopeptidase (CALLA), is underexpressed in SCLC cells and in bronchoalveolar lavage (BAL) fluid from smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of both SCLC and NSCLC occurs through stimulation of proliferation and mutagenesis occurring over years, and resulting from exposure to tobacco and other carcinogens. Multiple genetic defects have been detected; some are characteristic and perhaps involved with oncogenesis, whereas others are probably random or secondary events. A detailed discussion of the molecular genetic changes associated with small cell neuroendocrine tumors is beyond the scope of this review. The most common characteristics of SCLC are summarized below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      p53 mutations are detected in 75 to 90 percent of SCLCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Loss of heterozygosity of chromosomes 9p and 10q (the site of the PTEN gene) is present in the majority of tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deletion of 3p, including 3p21-22, leading to inactivation of as many as three putative tumor-suppressor genes. The FHIT gene (for fragile histidine triad), which is involved in the accumulation of diadenosine tetraphosphate, thereby leading to DNA synthesis and proliferation, has been localized to 3p14.2 and is believed to be an important tumor suppressor gene involved in the pathogenesis of lung cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/24\">",
"       24",
"      </a>",
"      ]. A second postulated tumor suppressor gene located at 3p21.3 is RASSF1A, which is absent in all SCLCs tested [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Deletion of a third gene, TGFBR2, located at 3p21.3.22, and encoding the transforming growth factor beta type II receptor, has also been described in SCLC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Loss of the retinoblastoma gene function at 13q14 is nearly ubiquitous in SCLC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. As an example, approximately 60 percent of SCLC cell lines have undetectable transcripts, while the remaining 40 percent have an abnormal gene product.",
"     </li>",
"     <li>",
"      Telomerase is a ribonucleoprotein enzyme that compensates for telomere shortening during cell division by synthesizing telomeric DNA, thereby maintaining telomere length. In normal somatic cells, telomerase activity is usually undetectable, with the exception of some cell types that possess the ability to divide indefinitely (eg, hematopoietic cells, hair follicles, intestinal crypt cells, and basal cells of the epidermis). Activation of telomerase is detected in approximately 90 percent of SCLCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/30\">",
"       30",
"      </a>",
"      ]. In cancer cells, telomerase activity correlates with the stabilization of telomere length and cellular immortalization.",
"     </li>",
"     <li>",
"      Upregulation of wild type c-kit and its phosphorylated form may represent another",
"      <span class=\"nowrap\">",
"       autocrine/paracrine",
"      </span>",
"      growth factor loop and is detected in up to 80 to 90 percent of SCLCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/31,32\">",
"       31,32",
"      </a>",
"      ], although",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      has not demonstrated activity in phase II trials.",
"     </li>",
"     <li>",
"      Through gene expression arrays and CCGH analyses, upregulation of the c-myc pathways, the islet-1 and the forkhead box protein G1B transcription factors appear to be characteristically upregulated in SCLCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/8,17,33\">",
"       8,17,33",
"      </a>",
"      ]. Other pathways have been shown to be abnormally regulated in SCLC, such as bcl2, although trials examining oblimersen have not yielded promising results. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8951?source=see_link\">",
"       \"Experimental approaches to treatment for small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to NSCLC, mutations in the EGFR and K-ras oncogenes and p16 abnormalities are rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCLC typically arise in the central airways, infiltrating the submucosa, and it gradually obstructs the bronchial lumen through extrinsic or endobronchial spread. The most common presentation is that of a large hilar mass with bulky mediastinal adenopathy. Potential clinical consequences include cough, dyspnea, weight loss, and debility, with or without postobstructive pneumonia. Approximately 70 percent of patients present with overt metastatic disease; SCLC has a particular propensity to spread to liver, adrenals, bone, bone marrow, and brain.",
"   </p>",
"   <p>",
"    SCLC can occasionally present as a peripheral nodule. However, a solitary peripheral nodule without central adenopathy is sufficiently uncommon that cytologic diagnosis from a fine needle aspirate might not adequately differentiate SCLC from typical or atypical carcinoid, or from a well-differentiated neuroendocrine tumor. In this situation, mediastinal staging followed by surgical resection is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38469?source=see_link\">",
"     \"Role of surgery in multimodality therapy for small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, small cell lung cancer can occasionally present with a paraneoplastic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two stage system originally introduced by the Veterans' Affairs Lung Study Group (VALSG) is widely utilized in staging of SCLC because of its simplicity and clinical utility:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited disease is defined as disease confined to the ipsilateral hemithorax and within a single radiotherapy port (corresponding in part to TNM stages I through IIIB, (",
"      <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"       table 3",
"      </a>",
"      )).",
"     </li>",
"     <li>",
"      Extensive disease is defined as evident metastatic disease outside the ipsilateral hemithorax.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At presentation, 60 to 70 percent of patients with SCLC have extensive stage, and 30 to 40 percent have limited stage disease. This distinction is clinically relevant, since patients with limited stage disease are generally treated with combined modality therapy, while those with extensive stage disease receive chemotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This schema is problematic when applied to patients with extremely limited disease or with locoregionally advanced disease, such as those with contralateral hilar or supraclavicular nodes, pericardial effusions, or malignant pleural effusions. Patients with features of more locally advanced disease are frequently excluded from protocols for limited stage disease, although the prognostic impact of these findings remains controversial (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognostic factors'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Not surprisingly, the extent of locoregional disease appears to correlate with survival in patients with limited stage disease who undergo combined modality therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     TNM staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the more descriptive TNM staging system for NSCLC that is advocated by IASLC (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 3",
"    </a>",
"    ) describes the extent and burden of disease more accurately than the VALSG schema, it is of limited value in most cases of SCLC because of an overlap in prognosis and therapy between stage groupings, particularly stage II and III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/39\">",
"     39",
"    </a>",
"    ]. It is useful for patients with SCLC that is limited to the ipsilateral lung (stage I disease), in whom resection followed by adjuvant chemotherapy may be feasible; however, this applies to fewer than 10 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38469?source=see_link\">",
"     \"Role of surgery in multimodality therapy for small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, the definition of \"limited disease\" in the",
"    <span class=\"nowrap\">",
"     TNM/IASLC",
"    </span>",
"    staging system includes any patient without distant metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/40\">",
"     40",
"    </a>",
"    ]. Although not in widespread use, this definition may provide better prognostic stratification than the VALSG definition of limited versus extensive disease. In one report that compared outcomes of patients with limited stage disease by VALSG or IASLC criteria, the prognosis of patients with limited disease by IASLC but not VALSG criteria was similar to that of others with limited stage disease by both criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Staging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy is required for all patients with SCLC, even those with radiographically limited stage disease. Therefore, the major therapeutic significance of staging is to guide the use of chest radiotherapy, which is indicated for limited but not necessarily for extensive disease. After a tissue diagnosis is made, an exhaustive staging workup includes physical examination, chest radiography, chest, liver, and adrenal computed tomography, head CT or cranial MRI (particularly for asymptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/41\">",
"     41",
"    </a>",
"    ]), bone scan, and, in selected cases, unilateral or bilateral bone marrow aspirates and biopsies. Bone marrow is involved in 15 to 30 percent of patients at presentation, but it represents a solitary site of metastatic disease in only 2 to 6 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outside of the context of a clinical trial, an alternate, abbreviated staging algorithm could be directed by symptoms and terminated as soon as extensive disease is documented. This latter strategy, the rule for many European trials, is likely to become more prevalent in the United States in this time of health care parsimony and need for economic justification. Specifically, given the relative invasiveness of bone marrow examination, many investigators argue that this test has a very low yield in patients with normal serum lactate dehydrogenase (LDH) levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arguments against sequential staging include the fact that bone scans are positive in up to 30 percent of patients without symptoms or an abnormal alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/34,42,43\">",
"     34,42,43",
"    </a>",
"    ]. Furthermore, head CT scan is positive in about 15 percent of patients at diagnosis, including 5 to 8 percent of asymptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/34,47,48\">",
"     34,47,48",
"    </a>",
"    ]. Early identification and treatment of brain metastases is important, as it results in a lower rate of chronic neurologic morbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of greater importance than the complete ascertainment of every involved site of disease is the rapid tempo of untreated SCLC. Most patients develop their prediagnosis symptoms within eight weeks. Staging should not delay treatment onset more than 7 to 10 days, as many patients will become seriously ill in the interval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Utility of PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) with 18-fluoro-2-deoxyglucose (FDG) is a noninvasive method to assess for mediastinal or distant metastases by detecting areas of high FDG uptake (ie, increased metabolic activity) consistent with malignancy. Although PET has been widely studied as a component of the staging evaluation for non-small cell lung cancers, less data are available on its role in patients with SCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28102?source=see_link\">",
"     \"Thoracic positron emission tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential role of PET in patients with SCLC is illustrated by a report of 51 patients who were studied with both PET and CT at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/51\">",
"     51",
"    </a>",
"    ]. PET detected the thoracic disease in all 51 (100 percent). In 18 cases, patients were classified as having limited stage disease based upon results of CT; of these, two (11 percent) were reclassified as having extensive stage disease based upon the results of PET. Of the 33 patients with extensive stage disease on CT scan, six (18 percent) were restaged as having limited stage disease using PET.",
"   </p>",
"   <p>",
"    If additional studies confirm these observations, it may be possible to omit other staging procedures such as bone scan and bone marrow biopsy during the initial evaluation of patients with SCLC.",
"   </p>",
"   <p>",
"    PET scanning has also been used to identify tumors with increased metabolic activity as manifested by a high maximal standardized uptake value (SUV). In one report, patients with a high SUV had a significantly shorter survival than those with a low SUV (median overall survival 12 versus 24 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17080?source=see_link&amp;anchor=H13#H13\">",
"     \"Computed tomographic and positron emission tomographic scanning of pulmonary nodules\", section on 'Metabolic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the time of diagnosis, the median ranges of survival for limited and extensive disease are 15 to 20 months and 8 to 13 months, respectively. Approximately 20 to 40 percent of limited stage and less than 5 percent of extensive stage patients survive two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The respective values for five-year survival are 10 to 13, and 1 to 2 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. The most important adverse prognostic factors are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The host factors of poor performance status and weight loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/60\">",
"       60",
"      </a>",
"      ]. Continuation of smoking also contributes to chemoresistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tumor-related factors such as the extent of disease (limited versus extensive). In limited disease, early stage disease (stage I) carries a favorable prognosis, while an elevated LDH is unfavorable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/58,62\">",
"       58,62",
"      </a>",
"      ]. In extensive disease, the number of organ sites involved is inversely related to prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/57\">",
"       57",
"      </a>",
"      ]. Metastatic involvement of the central nervous system, the marrow, or the liver is unfavorable compared to other sites, although these variables are confounded by the number of sites of involvement.",
"     </li>",
"     <li>",
"      In most trials, women fare better than men, although the reasons for this are not known.",
"     </li>",
"     <li>",
"      The presence of paraneoplastic syndromes is generally unfavorable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With longer duration of follow-up, the prognostic importance of many of these variables diminishes, largely as a result of the smaller numbers of long-term survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42552/abstract/58,63\">",
"     58,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/38/24162?source=see_link\">",
"       \"Patient information: Small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/8/22659?source=see_link\">",
"       \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small cell lung cancer (SCLC) is distinguished from non-small cell lung cancer (NSCLC) by its rapid doubling time, high growth fraction, and the early development of widespread metastases. Although SCLC is highly responsive to chemotherapy and radiotherapy, the disease usually relapses within two years despite treatment. Overall, only 3 to 8 percent of all patients with SCLC survive beyond five years. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCLC is generally diagnosed by light microscopy. It is characterized by small \"blue\" malignant cells about twice the size of lymphocytes. The cytoplasm is sparse, and nuclear features include finely dispersed chromatin without distinct nucleoli. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eight antigen clusters have been identified and multiple genetic defects have been detected in SCLC, especially deletion of 3p, including 3p21-22, and loss of RB1 function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Tumor markers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Genetic abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCLC typically arise in central airways of smokers, and due to their biological aggressiveness, have a brief period of pre-diagnosis symptoms, yet present with overt metastatic disease in two-thirds of patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCLC is the most common malignancy associated with neurologic paraneoplastic syndromes and is frequently associated with ectopic hormonal syndromes such as SIADH and Cushing's Syndrome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Tumor markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although chemotherapy remains the mainstay of therapy, chest radiotherapy given concurrently with chemotherapy increases the likelihood of long-term (two and five year) survival for patients with limited stage disease. Prophylactic brain radiation is also a component of usual treatment. Thus, extensive staging is indicated to detect whether overt metastases are present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9914?source=see_link\">",
"       \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/1\">",
"      Ettinger DS, Aisner J. Changing face of small-cell lung cancer: real and artifact. J Clin Oncol 2006; 24:4526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/2\">",
"      Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/3\">",
"      Hirsch FR, Matthews MJ, Aisner S, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 1988; 62:973.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart, IARC Press, Lyon 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/5\">",
"      Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244.",
"     </a>",
"    </li>",
"    <li>",
"     Travis, WD.. The concept of pulmonary neuroendocrine tumours.. In: Pathology &amp; Genetics: Tumours of the Lung, Pleura, Thymus, and Heart., Travis, WD, Brambilla, E, Muller-Hermelink, HK, Harris, CC. (Eds), IARC Press, Lyon 2004. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/7\">",
"      Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004; 363:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/8\">",
"      Peng WX, Shibata T, Katoh H, et al. Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumors of the lung. Cancer Sci 2005; 96:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/9\">",
"      Adelstein DJ, Tomashefski JF Jr, Snow NJ, et al. Mixed small cell and non-small cell lung cancer. Chest 1986; 89:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/10\">",
"      Mangum MD, Greco FA, Hainsworth JD, et al. Combined small-cell and non-small-cell lung cancer. J Clin Oncol 1989; 7:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/11\">",
"      Baker RR, Ettinger DS, Ruckdeschel JD, et al. The role of surgery in the management of selected patients with small-cell carcinoma of the lung. J Clin Oncol 1987; 5:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/12\">",
"      Souhami RL, Beverley PC, Bobrow LG, Ledermann JA. Antigens of lung cancer: results of the second international workshop on lung cancer antigens. J Natl Cancer Inst 1991; 83:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/13\">",
"      Guinee DG Jr, Fishback NF, Koss MN, et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994; 102:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/14\">",
"      Junker K, Wiethege T, M&uuml;ller KM. Pathology of small-cell lung cancer. J Cancer Res Clin Oncol 2000; 126:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/15\">",
"      King KA, Hua J, Torday JS, et al. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Invest 1993; 91:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/16\">",
"      Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/17\">",
"      Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancers. Semin Oncol 2004; 31:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/18\">",
"      Miller CW, Simon K, Aslo A, et al. p53 mutations in human lung tumors. Cancer Res 1992; 52:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/19\">",
"      Takahashi T, Takahashi T, Suzuki H, et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991; 6:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/20\">",
"      D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992; 7:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/21\">",
"      Kim SK, Ro JY, Kemp BL, et al. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res 1997; 57:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/22\">",
"      Hosoya Y, Gemma A, Seike M, et al. Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis. Lung Cancer 1999; 25:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/23\">",
"      Virmani AK, Fong KM, Kodagoda D, et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998; 21:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/24\">",
"      Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996; 85:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/25\">",
"      Burbee DG, Forgacs E, Z&ouml;chbauer-M&uuml;ller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/26\">",
"      Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/27\">",
"      Hougaard S, N&oslash;rgaard P, Abrahamsen N, et al. Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines. Br J Cancer 1999; 79:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/28\">",
"      Helin K, Holm K, Niebuhr A, et al. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci U S A 1997; 94:6933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/29\">",
"      Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002; 21:6908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/30\">",
"      Sarvesvaran J, Going JJ, Milroy R, et al. Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 1999; 20:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/31\">",
"      Rohr UP, Rehfeld N, Pflugfelder L, et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 2004; 111:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/32\">",
"      Tamborini E, Bonadiman L, Negri T, et al. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 2004; 10:8214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/33\">",
"      Kim YH, Girard L, Giacomini CP, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 2006; 25:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/34\">",
"      Urban T, Chastang C, Vaylet F, et al. Prognostic significance of supraclavicular lymph nodes in small cell lung cancer: a study from four consecutive clinical trials, including 1,370 patients. \"Petites Cellules\" Group. Chest 1998; 114:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/35\">",
"      Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 2001; 7:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/36\">",
"      Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer 2002; 37:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/37\">",
"      Shepherd FA, Ginsberg RJ, Haddad R, et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 1993; 11:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/38\">",
"      Kreisman H, Wolkove N, Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule. Chest 1992; 101:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/39\">",
"      Valli&egrave;res E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/40\">",
"      Mountain CF. A new international staging system for lung cancer. Chest 1986; 89:225S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/41\">",
"      Hochstenbag MM, Twijnstra A, Wilmink JT, et al. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol 2000; 48:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/42\">",
"      Ihde DC, Makuch RW, Carney DN, et al. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 1981; 123:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/43\">",
"      Levitan N, Byrne RE, Bromer RH, et al. The value of the bone scan and bone marrow biopsy staging small cell lung cancer. Cancer 1985; 56:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/44\">",
"      Tritz DB, Doll DC, Ringenberg QS, et al. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer 1989; 63:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/45\">",
"      Ihde DC, Simms EB, Matthews MJ, et al. Bone marrow metastases in small cell carcinoma of the lung: frequency, description, and influence on chemotherapeutic toxicity and prognosis. Blood 1979; 53:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/46\">",
"      Hamrick RM 3rd, Murgo AJ. Lactate dehydrogenase values and bone scans as predictors of bone marrow involvement in small-cell lung cancer. Arch Intern Med 1987; 147:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/47\">",
"      Hardy J, Smith I, Cherryman G, et al. The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. Br J Cancer 1990; 62:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/48\">",
"      Rosen ST, Makuch RW, Lichter AS, et al. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response. Am J Med 1983; 74:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/49\">",
"      Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; 22:3248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/50\">",
"      Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007; 18:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/51\">",
"      Vinjamuri M, Craig M, Campbell-Fontaine A, et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008; 9:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/52\">",
"      Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/53\">",
"      van Loon J, Offermann C, Bosmans G, et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol 2008; 87:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/54\">",
"      Lee YJ, Cho A, Cho BC, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 2009; 15:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/55\">",
"      Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988; 15:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/56\">",
"      Osterlind K, Hansen HH, Hansen M, et al. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 1986; 4:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/57\">",
"      Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991; 99:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/58\">",
"      Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol 1995; 13:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/59\">",
"      Tai P, Tonita J, Yu E, Skarsgard D. Twenty-year follow-up study of long-term survival of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. Int J Radiat Oncol Biol Phys 2003; 56:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/60\">",
"      Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000; 89:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/61\">",
"      Mart&iacute;nez-Garc&iacute;a E, Irigoyen M, Gonz&aacute;lez-Moreno O, et al. Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci 2010; 116:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/62\">",
"      Byhardt RW, Hartz A, Libnoch JA, et al. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys 1986; 12:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42552/abstract/63\">",
"      Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61:597.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4628 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42552=[""].join("\n");
var outline_f41_35_42552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classification of SCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TNM staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Staging workup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Utility of PET scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/11/31933\" title=\"table 1\">",
"      Proposed IASLC ATS ERS classification small biopsies cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/32/13836\" title=\"table 2\">",
"      WHO neuroendo tum lung 2004",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/41/37533\" title=\"table 3\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17080?source=related_link\">",
"      Computed tomographic and positron emission tomographic scanning of pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8951?source=related_link\">",
"      Experimental approaches to treatment for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/38/24162?source=related_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38469?source=related_link\">",
"      Role of surgery in multimodality therapy for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28102?source=related_link\">",
"      Thoracic positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2744?source=related_link\">",
"      Treatment of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_35_42553="Evaluation and treatment of premenopausal osteoporosis";
var content_f41_35_42553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and treatment of premenopausal osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42553/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42553/contributors\">",
"     Carolyn B Becker, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42553/contributors\">",
"     Adi Cohen, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42553/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/35/42553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/35/42553/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/35/42553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data exist to guide clinical care for premenopausal women who have low bone density (Z score less than or equal to -2.0)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fragility fractures. The guidelines for the treatment of osteoporosis based on bone mineral density (BMD) in postmenopausal women do not generally apply to premenopausal women as the relationship between bone mass and fracture in premenopausal women is not the same as in postmenopausal women. BMD alone should not be used to define osteoporosis in a premenopausal woman, but, like fragility fractures, is an indication for further evaluation.",
"   </p>",
"   <p>",
"    This topic reviews the evaluation and treatment of premenopausal osteoporosis. The epidemiology and etiology are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=see_link\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone density screening is not routinely recommended for premenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/1\">",
"     1",
"    </a>",
"    ]. However, healthy premenopausal women with concerns about bone health or risk factors for osteoporosis may request a bone mineral density (BMD) test and seek expert advice if results are abnormal. A number of major organizations provide recommendations for BMD testing in premenopausal women (",
"    <a class=\"graphic graphic_table graphicRef71784 \" href=\"mobipreview.htm?11/59/12220\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although routine BMD screening of premenopausal or perimenopausal women is not currently recommended, some studies have shown beneficial outcomes when BMD testing is combined with education about bone health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As an example, in one study of 669 premenopausal women (3.8 percent with fractures), osteoporosis education coupled with BMD testing resulted in positive lifestyle changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/2\">",
"     2",
"    </a>",
"    ]. Twelve months following the intervention, women were less likely to smoke, use alcohol, or consume caffeinated beverages, and those with low BMD were more likely to take calcium and vitamin D supplements compared with women with normal BMD.",
"   </p>",
"   <p>",
"    We agree with the International Society of Clinical Densitometry (ISCD) guidelines that suggest BMD screening for premenopausal women under the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of a fragility fracture",
"     </li>",
"     <li>",
"      Known secondary causes of osteoporosis (",
"      <a class=\"graphic graphic_table graphicRef64403 \" href=\"mobipreview.htm?12/47/13052\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of low bone mass in premenopausal women may be related to failure to attain expected peak bone mass, previous bone loss, or ongoing bone loss. The goal of the evaluation is to distinguish between these groups since the treatment approach differs.",
"   </p>",
"   <p>",
"    The evaluation typically begins with a history, physical examination, and biochemical testing. If this initial evaluation is unrevealing, it is possible that the patient never achieved optimal peak bone mass or that insults to the skeleton occurred in the past and are no longer active; this can best be confirmed by serial bone density or biochemical markers of bone turnover. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Additional evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women who come to medical attention in the setting of a fragility fracture or after learning of low BMD (Z score &le;-2.0) should have an evaluation to identify potential secondary causes. Premenopausal women with a fragility fracture require this evaluation for secondary causes even if the BMD is normal. A secondary cause of osteoporosis can be found in a substantial proportion of premenopausal women with osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], and identification of a contributing condition often helps to guide management of the affected individual.",
"   </p>",
"   <p>",
"    Secondary etiologies are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef64403 \" href=\"mobipreview.htm?12/47/13052\">",
"     table 2",
"    </a>",
"    ). Most of these conditions can be excluded with a careful history and physical examination. Laboratory evaluation may help to diagnose secondary causes of osteoporosis, such as renal or liver disease, hyperthyroidism, hyperparathyroidism, Cushing's syndrome or subclinical hypercortisolism, early menopause, celiac disease and other forms of malabsorption, idiopathic hypercalciuria, or rarely, connective tissue disorders.",
"   </p>",
"   <p>",
"    We suggest that all premenopausal women with low BMD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fragility fracture have the following basic tests (",
"    <a class=\"graphic graphic_table graphicRef53634 \" href=\"mobipreview.htm?5/47/5884\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Calcium, phosphate, creatinine",
"     </li>",
"     <li>",
"      Alkaline phosphatase, aminotransferases",
"     </li>",
"     <li>",
"      25-hydroxyvitamin D",
"     </li>",
"     <li>",
"      TSH",
"     </li>",
"     <li>",
"      24-hour urine for calcium and creatinine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have abnormalities on the initial laboratory testing, who have suspicious findings on history and physical examination, or who have unexplained osteoporosis and fracture after the initial evaluation require additional laboratory tests (",
"    <a class=\"graphic graphic_table graphicRef53634 \" href=\"mobipreview.htm?5/47/5884\">",
"     table 3",
"    </a>",
"    ). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with anemia, low urinary calcium excretion,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low vitamin D levels should be tested for celiac disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H21#H21\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Metabolic bone disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum PTH should be measured in patients with hypercalcemia, hypercalciuria, or a history of renal stones. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=see_link\">",
"       \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary cortisol excretion should be measured if Cushing's syndrome is suspected and also in patients with unexplained osteoporosis and vertebral fracture, since patients with subclinical hypercortisolism (mild hypercortisolism without clinical manifestations of Cushing's syndrome) are at risk for low BMD and fractures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Bone loss'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link&amp;anchor=H18#H18\">",
"       \"The adrenal incidentaloma\", section on 'Subclinical Cushing's syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=see_link\">",
"       \"Establishing the diagnosis of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some women may have genetically determined low peak bone mass. Other women may have accrued less bone than expected due to insults to the skeleton (eg, medications, poor nutrition, estrogen deficiency) that occurred during adolescence and are no longer present at the time of evaluation. In either case, these women should have stable BMD, even though BMD is low. This is in contrast to women with continued declines in BMD who may have an ongoing secondary cause. Serial BMD measurements, if available, are helpful in making this distinction.",
"   </p>",
"   <p>",
"    If there is only a single measurement of BMD, obtaining serum or urine markers of bone turnover may provide useful information. Specimens must often be collected fasting in the morning hours for proper interpretation. If markers of resorption are elevated above the premenopausal range, ongoing bone resorption is more likely. However, the range of normal is wide in premenopausal women, making interpretation difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/7\">",
"     7",
"    </a>",
"    ]. Additionally, markers of bone resorption must be interpreted according to the patient's age. Adolescence and young adulthood are characterized by active bone modeling and physiologic increases in markers of bone turnover. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Premenopausal women with bone fragility and no identifiable etiology after extensive evaluation for secondary causes are said to have idiopathic osteoporosis. In patients with a history of fragility fractures without a known cause, iliac crest bone biopsy may be indicated to identify other sources of bone fragility and to guide therapeutic interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium, vitamin D, and weight bearing exercise are recommended for most women with premenopausal osteoporosis. Pharmacologic therapies that have shown antifracture efficacy in postmenopausal women include bisphosphonates, SERMs, parathyroid hormone (PTH), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    . However, there are very few data available to guide clinicians in the use of these medications in premenopausal women and virtually no data on efficacy or safety of these therapies in premenopausal women without secondary causes of osteoporosis.",
"   </p>",
"   <p>",
"    In premenopausal women with low BMD alone, without fractures, known secondary causes for low BMD, or evidence of accelerated bone loss, pharmacotherapy is almost never indicated. If markers of bone turnover are in the lower end of normal range for premenopausal women and serial BMD measurements are not available, it may be reasonable to treat with calcium and vitamin D and repeat a bone density study in one year.",
"   </p>",
"   <p>",
"    Women with fractures or accelerated bone loss in the setting of estrogen deficiency or amenorrhea may benefit from estrogen replacement. In women with normal gonadal function or in those who cannot take estrogen, bisphosphonates are generally the drugs of choice in the rare cases when pharmacologic therapy is indicated. For women receiving chronic glucocorticoids, teriparatide (parathyroid hormone 1-34) may also be considered. For women with osteogenesis imperfecta, bisphosphonates are the treatment of choice. For women found to have a secondary cause of osteoporosis, the management often depends on the underlying etiology. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Secondary causes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, lifestyle modifications should be encouraged for all women with low bone mass since peak bone mass may not occur until well into the fourth decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Positive lifestyle changes include adequate calcium and vitamin D intake (1000 mg elemental calcium and 600 int. units vitamin D daily) (",
"    <a class=\"graphic graphic_table graphicRef59927 \" href=\"mobipreview.htm?1/37/1627\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], regular weight bearing exercise and physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/14\">",
"     14",
"    </a>",
"    ], cessation of smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], achievement of normal body weight, avoidance of excessive dieting and wide swings in weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/17\">",
"     17",
"    </a>",
"    ], and moderation in alcohol consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is a history of nephrolithiasis, additional evaluation, such as measurement of PTH and 1,25 dihydroxyvitamin D levels, is required before making supplementation recommendations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An observational study of 16 premenopausal women with idiopathic osteoporosis (mean age 35.7 years) followed for 3.1 years and treated with increased dietary calcium and physical activity revealed significant increases in lumbar spine and femoral neck BMD after two or three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intensity of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no convincing evidence that high-intensity exercise such as running is of greater benefit than lower intensity exercise such as walking. Because enjoyment of the regimen is important (the benefits of exercise are quickly lost after the woman stops exercising) we recommend that women pick a regular weight bearing exercise regimen that they enjoy to facilitate long-term compliance. Excessive exercise in premenopausal women may lead to weight loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypothalamic amenorrhea, exacerbating low bone density. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=see_link&amp;anchor=H31379420#H31379420\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Endocrine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pharmacologic therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with amenorrhea from various causes, treatment should be directed at the underlying cause. If resumption of menses is unlikely, estrogen therapy is usually the treatment of choice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=see_link&amp;anchor=H27332237#H27332237\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Osteoporosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks of estrogen therapy in premenopausal women are lower than in older postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .) However, risks must be considered related to age and other clinical factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H3033285#H3033285\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few randomized controlled trials of antiresorptive therapy in premenopausal women with osteoporosis. Studies demonstrating the benefits of bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis included some premenopausal women. As a result, both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    have been approved by the United States Food and Drug Administration for use in premenopausal women receiving glucocorticoids.",
"    <br/>",
"    <br/>",
"    Although bisphosphonates have been shown to prevent bone loss in young women with various conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/20-29\">",
"     20-29",
"    </a>",
"    ], it should be kept in mind that long-term efficacy and safety data are scarce in premenopausal women. The decision to initiate treatment with bisphosphonates in any premenopausal woman should be made on a case by case basis with consideration of individual fracture risk and potential medication effects. In general, the goal should be for the shortest possible duration of bisphosphonate use, particularly in light of data regarding rare potential risks of long-term use, such as osteonecrosis of the jaw [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] and atypical femoral fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates carry a Category C rating for safety in pregnancy due to toxic effects in pregnant rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/32\">",
"     32",
"    </a>",
"    ]. Bisphosphonates crossed the placenta and accumulated in fetal bones in an experimental rat model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/33\">",
"     33",
"    </a>",
"    ]. Human data on the safety of bisphosphonates in pregnancy are anecdotal and sparse, as the following studies illustrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pharmacovigilance study in England reported two normal pregnancies in women taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A woman with malignant hypercalcemia, treated during the third trimester of pregnancy with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      , gave birth to a normal fetus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two women with osteogenesis imperfecta (OI) treated with long-term intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      prior to conception had normal pregnancies, deliveries, but mild neonatal abnormalities (transient hypocalcemia in one fetus and bilateral talipes equinovarus in the other) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Four cases of women with OI or polyostotic fibrous dysplasia who received prolonged IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      therapy pre-pregnancy showed no adverse maternal or fetal outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nine women with pregnancy-associated osteoporosis who received at least one bisphosphonate for a median duration of 24 months were studied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/29\">",
"       29",
"      </a>",
"      ]. There were no negative pregnancy outcomes reported in the five women who received bisphosphonates and went on to have subsequent pregnancies.",
"     </li>",
"     <li>",
"      Twenty-one women receiving oral or intravenous bisphosphonates during the first trimester of pregnancy (n = 15) and six women who stopped bisphosphonate therapy within three months prior to conception were compared with 21 healthy pregnant controls. There were no differences in any pregnancy or neonatal outcomes, including major birth defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, the rodent data coupled with the long half-life of bisphosphonates in bone make the use of these agents in reproductive age women problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7269673\">",
"    <span class=\"h3\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous parathyroid hormone (teriparatide) has been used successfully in clinical trials to prevent bone loss in premenopausal women on GnRH agonists for the treatment of endometriosis and in premenopausal women taking glucocorticoids. Teriparatide is currently approved for the treatment of glucocorticoid-induced osteoporosis. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link&amp;anchor=H14#H14\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Parathyroid hormone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Teriparatide has been associated with osteosarcoma in animal studies. Use of this medication should be avoided in those at increased risk of osteosarcoma (including those with Paget&rsquo;s disease, prior radiation, or unexplained elevation in alkaline phosphatase). Thus, this medication should be used with great caution in young women, and use should be avoided in those with delayed growth or open epiphyses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H27#H27\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Adverse events'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H44#H44\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selective estrogen receptor modulators (SERMs) &mdash; SERMs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      should not be used to treat osteoporosis in menstruating women as they block estrogen action on bone, leading to further bone loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=see_link\">",
"       \"Selective estrogen receptor modulators for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Calcitonin &mdash; There are few published studies on the safety or efficacy of salmon calcitonin in young women. However, in one double-blind study of 120 perimenopausal women treated with 100 int. units intranasal calcitonin or placebo spray daily, there was no improvement in BMD or bone markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      &mdash; Use of this newer agent may be considered in those with rapid bone loss or multiple fractures in whom other agents are contraindicated. However, efficacy and safety of this medication have not been defined in premenopausal women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link&amp;anchor=H9#H9\">",
"       \"Denosumab for osteoporosis\", section on 'Candidates for therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9986554\">",
"    <span class=\"h2\">",
"     High risk for ongoing bone loss or fracture",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women on chronic glucocorticoids for a variety of inflammatory or autoimmune conditions present a special therapeutic challenge.",
"   </p>",
"   <p>",
"    Glucocorticoids reduce the production of sex steroids. As a result, it is logical to replace these hormones if the patient is deficient (as suggested by symptoms such as amenorrhea in premenopausal women). We suggest an estrogen-progestin oral contraceptive pill (if not contraindicated) in premenopausal women with amenorrhea who are initiating or taking glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H3033285#H3033285\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically reserve the use of bisphosphonates for premenopausal women taking or initiating glucocorticoids (&ge;7.5 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent), who have a fragility fracture, and who are not candidates for or are intolerant of estrogen replacement therapy (eg, oral contraceptives). Teriparatide is an alternative option for women with fully fused epiphyses who have severe glucocorticoid-induced osteoporosis and fragility fractures, particularly at the spine, and who do not need estrogen replacement therapy because they have normal menstrual function. We urge great caution in the use of bisphosphonates and teriparatide in young women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link&amp;anchor=H622811#H622811\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Premenopausal women and younger men'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link&amp;anchor=H2707796#H2707796\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates are very efficacious agents in the prevention and treatment of glucocorticoid-induced bone loss, but few premenopausal women were included in the large clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/45\">",
"     45",
"    </a>",
"    ]. Two clinical trials that included premenopausal women with corticosteroid-treated connective tissue diseases (CTD) used the less potent first-generation bisphosphonate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    , as the antiresorptive agent and found successful maintenance of BMD in the women taking the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a study of 30 premenopausal women with active CTD (mainly lupus) on high dose glucocorticoids showed significant bone loss at 12 months at both the lumbar spine and total hip despite calcium (500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and cholecalciferol (25,000 int.",
"    <span class=\"nowrap\">",
"     units/month).",
"    </span>",
"    However, those patients randomly assigned to calcium, vitamin D, and oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    maintained BMD at the spine but lost at the hip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/48\">",
"     48",
"    </a>",
"    ]. The failure of oral pamidronate to prevent bone loss may be due to the high doses of glucocorticoids used in this trial.",
"   </p>",
"   <p>",
"    Parathyroid hormone 1-34 (teriparatide) stimulates bone formation as well as resorption, and intermittent administration stimulates formation more than resorption. Initial studies show that it is beneficial in patients with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .) This benefit also appears to apply to premenopausal women with glucocorticoid-induced osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/49\">",
"     49",
"    </a>",
"    ]. In a secondary analysis of a randomized trial of teriparatide versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    in patients with glucocorticoid-induced osteoporosis, the increase in lumbar spine BMD was significantly greater in the teriparatide group for both premenopausal (7.0 versus 0.7 percent) and postmenopausal (7.8 versus 3.7 percent) women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/50\">",
"     50",
"    </a>",
"    ]. In premenopausal women, fractures were infrequent in both treatment groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link&amp;anchor=H14#H14\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Parathyroid hormone'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In premenopausal women included in the clinical trials for glucocorticoid-induced osteoporosis, fractures are generally infrequent in both treated and control groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Because fracture risk in premenopausal women on glucocorticoids is not clearly defined and may differ from reported fracture risk in other glucocorticoid-treated populations, and because of the potential pregnancy-related risks of bisphosphonate use that are unique to premenopausal women, the American College of Rheumatology (ACR) provides therapeutic guidelines particularly for premenopausal women of childbearing potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/53\">",
"     53",
"    </a>",
"    ]. The ACR guidelines recommend consideration of bisphosphonate treatment for high risk (eg, previous fragility fracture) premenopausal women of childbearing potential taking at least 7.5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent per day over &ge;3 months. Teriparatide is an alternative option for such women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link&amp;anchor=H21#H21\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women receiving chemotherapy for breast cancer represent another group at risk for rapid bone loss. The incidence of chemotherapy-induced amenorrhea can range from 26 to 89 percent depending on the drugs used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/54\">",
"     54",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , 5-fluorouracil (CMF), and the GnRH agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    induce amenorrhea. However, amenorrhea induced by goserelin is reversible in the majority of patients following cessation of therapy, but permanent in most patients treated with CMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who have premature menopause as a result of chemotherapy can lose bone rapidly compared to women who maintain menses throughout chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/56\">",
"     56",
"    </a>",
"    ]. Prospective studies demonstrate bone loss at one year varying from 4 to 8 percent in the spine and 2 to 4 percent at the hip in premenopausal women who become amenorrheic after receiving adjuvant chemotherapy with CMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/20,21,57\">",
"     20,21,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\", section on 'Chemotherapy-induced amenorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In postmenopausal women with estrogen-dependent breast cancer,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    preserves bone mass and reduces symptomatic fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in premenopausal women, this is not the case. After three years of follow-up, women treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    who continued to menstruate following chemotherapy lost 4.6 percent of lumbar spine BMD while those who did not receive tamoxifen remained stable. Women who became amenorrheic after chemotherapy lost less bone at the lumbar spine on tamoxifen compared with amenorrheic controls but still had significant declines (6.8 percent BMD loss compared with 9.5 percent loss in nontreated women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/42\">",
"     42",
"    </a>",
"    ]. Despite its anti-estrogenic effects on the breast, tamoxifen has some estrogen-agonist effects in the skeletons of postmenopausal (but not premenopausal) women. In premenopausal women, tamoxifen blocks estrogen action on bone.",
"   </p>",
"   <p>",
"    Bisphosphonates successfully prevent bone loss in premenopausal women with newly diagnosed breast cancer treated with chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. For women with chemotherapy-induced menopause and low BMD (T-score &lt;-2.5)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fragility fracture, we suggest bisphosphonates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=see_link\">",
"     \"Overview of the use of osteoclast inhibitors in early breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aromatase inhibitors (AIs) are now used with increasing frequency in women with estrogen receptor positive breast cancer. AIs are associated with significant bone loss and increased risk of fracture. The management of aromatase inhibitor-induced bone loss is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Osteogenesis imperfecta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another group of premenopausal women at increased risk for fractures are those with osteogenesis imperfecta (OI). Given the very high morbidity of this inherited collagen disorder, antiresorptive therapy with bisphosphonates is recommended even in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite concerns about adverse effects of bisphosphonates on the intrinsic material properties of bone, iliac crest biopsies from children treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    for 2.5 years have not shown any negative effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/61\">",
"     61",
"    </a>",
"    ]. Both oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and intravenous pamidronate have been used successfully in children and adults with OI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/60,62\">",
"     60,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is important to avoid bisphosphonates in patients with OI Type VI since these drugs may worsen the defective bone mineralization found in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26185?source=see_link\">",
"     \"Osteogenesis imperfecta: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Secondary causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases where a secondary cause is found, treatment should be targeted to that specific disease or abnormality. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eliminating gluten from the diet of young women diagnosed with celiac disease leads to marked improvement in BMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parathyroidectomy in premenopausal women with primary hyperparathyroidism results in improvement in BMD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of primary hyperparathyroidism\", section on 'Bone disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with bone loss due to depot",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      have improvement in BMD upon discontinuation of the drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/65,66\">",
"       65,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral contraceptive therapy given to women with oligo- or amenorrhea, women with endometriosis on gonadotropin-releasing hormone (GnRH) therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/67\">",
"       67",
"      </a>",
"      ], or women experiencing perimenopausal bone loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/68\">",
"       68",
"      </a>",
"      ], significantly reduces bone loss.",
"     </li>",
"     <li>",
"      The selective estrogen receptor modulator,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      , stops bone loss in premenopausal women receiving GnRH agonist therapy for uterine leiomyomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/35/42553/abstract/69\">",
"       69",
"      </a>",
"      ]. This is in contrast to premenopausal women with breast cancer and chemotherapy-induced amenorrhea who continue to lose bone despite therapy with another SERM,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H15\">",
"       'Chemotherapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Weight gain and resumption of normal menstrual function appears necessary for skeletal recovery in patients with anorexia nervosa. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=see_link&amp;anchor=H27332237#H27332237\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Osteoporosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone density measurement is recommended for premenopausal women with known secondary causes of osteoporosis or history of a fragility fracture. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Screening'",
"      </a>",
"      above.) We do not suggest routine screening of premenopausal women for osteoporosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The goals of the evaluation of premenopausal women with low bone mass or fragility fracture are to rule out secondary causes and to determine if there is ongoing bone loss. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many secondary etiologies of low BMD can be determined based upon history and physical examination. In addition, all women with low BMD or fragility fracture should have basic laboratory testing (",
"      <a class=\"graphic graphic_table graphicRef53634 \" href=\"mobipreview.htm?5/47/5884\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on the results of the history, physical examination, and basic laboratory testing, more extensive testing may be indicated (",
"      <a class=\"graphic graphic_table graphicRef53634 \" href=\"mobipreview.htm?5/47/5884\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend adequate calcium, vitamin D, and exercise in all premenopausal women with low bone mass (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Elemental calcium (from diet and supplements) of 1000 mg and 600 int. units vitamin D daily is recommended. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with a secondary cause of low BMD, treatment should be targeted to that cause. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Secondary causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For premenopausal women of childbearing potential taking or initiating glucocorticoids who have amenorrhea, we suggest oral contraceptive or hormone replacement therapy (if not contraindicated) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Bisphosphonates are an option for women with fragility fractures or accelerated bone loss (&ge;4",
"      <span class=\"nowrap\">",
"       percent/year)",
"      </span>",
"      while receiving glucocorticoids (7.5 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      equivalent for &ge;3 months) who do not need estrogen replacement therapy because they have normal menstrual function. Teriparatide is an alternative option for such women, as long as epiphyses are fully fused. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Estrogen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link&amp;anchor=H2707796#H2707796\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Choice of therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Potential short- and long-term risks, as well as potential effects on the fetus, should be considered as part of the decision to use bisphosphonates or teriparatide for the treatment of premenopausal osteoporosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with chemotherapy-induced early menopause with low BMD (T-score &lt;-2.5)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fragility fracture, we suggest bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of the use of osteoclast inhibitors in early breast cancer\", section on 'Prevention of treatment-related bone loss'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of evidence of accelerated bone loss, we suggest conservative management without specific medical therapy for premenopausal women with isolated low bone mass (no fragility fractures and no known secondary cause) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These women should have a repeat bone density measurement in one year to ensure stable BMD. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In premenopausal women, idiopathic osteoporosis with repetitive fragility fractures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bone loss on serial BMD measurements is rare. Rather than empiric treatment, we suggest referral to metabolic bone specialists for further evaluation and possible bone biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/1\">",
"      Lewiecki EM. Premenopausal bone health assessment. Curr Rheumatol Rep 2005; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/2\">",
"      Jamal SA, Ridout R, Chase C, et al. Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study. J Bone Miner Res 1999; 14:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/3\">",
"      Jones G, Scott F. Low bone mass in premenopausal parous women: identification and the effect of an information and bone density feedback program. J Clin Densitom 1999; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/4\">",
"      Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008; 43:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/5\">",
"      Khosla S, Lufkin EG, Hodgson SF, et al. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994; 15:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/6\">",
"      Khan AA, Syed Z. Bone densitometry in premenopausal women: synthesis and review. J Clin Densitom 2004; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/7\">",
"      Rubin MR, Schussheim DH, Kulak CA, et al. Idiopathic osteoporosis in premenopausal women. Osteoporos Int 2005; 16:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/8\">",
"      Kann PH, Pf&uuml;tzner A, Delling G, et al. Transiliac bone biopsy in osteoporosis: frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years. Clin Rheumatol 2006; 25:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/9\">",
"      Anderson JJ, Rondano PA. Peak bone mass development of females: can young adult women improve their peak bone mass? J Am Coll Nutr 1996; 15:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/10\">",
"      Gourlay ML, Brown SA. Clinical considerations in premenopausal osteoporosis. Arch Intern Med 2004; 164:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/11\">",
"      Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/12\">",
"      Winzenberg TM, Shaw K, Fryer J, Jones G. Calcium supplementation for improving bone mineral density in children. Cochrane Database Syst Rev 2006; :CD005119.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Report at a Glance, Report Brief: Dietary Reference Intakes for Calcium and Vitamin D, released 11/30/2010. file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx (Accessed on December 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/14\">",
"      Martyn-St James M, Carroll S. Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis. J Bone Miner Metab 2010; 28:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/15\">",
"      Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/16\">",
"      MacInnis RJ, Cassar C, Nowson CA, et al. Determinants of bone density in 30- to 65-year-old women: a co-twin study. J Bone Miner Res 2003; 18:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/17\">",
"      Bacon L, Stern JS, Keim NL, Van Loan MD. Low bone mass in premenopausal chronic dieting obese women. Eur J Clin Nutr 2004; 58:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/18\">",
"      Tudor-Locke C, McColl RS. Factors related to variation in premenopausal bone mineral status: a health promotion approach. Osteoporos Int 2000; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/19\">",
"      Peris P, Monegal A, Mart&iacute;nez MA, et al. Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol 2007; 26:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/20\">",
"      Saarto T, Blomqvist C, V&auml;lim&auml;ki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/21\">",
"      Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/22\">",
"      Fuleihan Gel-H, Salamoun M, Mourad YA, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:3209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/23\">",
"      Greenspan SL, Bhattacharya RK, Sereika SM, et al. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007; 92:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/24\">",
"      Vehmanen L, Saarto T, Risteli J, et al. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2004; 87:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/25\">",
"      Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 2008; 26:4289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/26\">",
"      Tauchmanov&agrave; L, De Simone G, Musella T, et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/27\">",
"      Miller KK, Grieco KA, Mulder J, et al. Effects of risedronate on bone density in anorexia nervosa. J Clin Endocrinol Metab 2004; 89:3903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/28\">",
"      Golden NH, Iglesias EA, Jacobson MS, et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005; 90:3179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/29\">",
"      O'Sullivan SM, Grey AB, Singh R, Reid IR. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 2006; 17:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/30\">",
"      Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/31\">",
"      Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/32\">",
"      Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 1993; 121:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/33\">",
"      Patlas N, Golomb G, Yaffe P, et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999; 60:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/34\">",
"      Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 2008; 30:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/35\">",
"      Biswas PN, Wilton LV, Shakir SA. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003; 14:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/36\">",
"      Illidge TM, Hussey M, Godden CW. Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 1996; 8:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/37\">",
"      Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004; 19:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/38\">",
"      Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 2006; 91:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/39\">",
"      Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009; 44:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/40\">",
"      Papapoulos SE. Bisphosphonate actions: physical chemistry revisited. Bone 2006; 38:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/41\">",
"      McNicholl DM, Heaney LG. The safety of bisphosphonate use in pre-menopausal women on corticosteroids. Curr Drug Saf 2010; 5:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/42\">",
"      Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/43\">",
"      Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/44\">",
"      Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996; 18:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/45\">",
"      Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000; :CD001347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/46\">",
"      Nakayamada S, Okada Y, Saito K, Tanaka Y. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 2004; 31:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/47\">",
"      Sato S, Ohosone Y, Suwa A, et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. J Rheumatol 2003; 30:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/48\">",
"      Nzeusseu Toukap A, Depresseux G, Devogelaer JP, Houssiau FA. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus 2005; 14:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/49\">",
"      Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/50\">",
"      Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/51\">",
"      Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/52\">",
"      Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/53\">",
"      Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/54\">",
"      Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997; 43:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/55\">",
"      Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003; 14:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/56\">",
"      Headley JA, Theriault RL, LeBlanc AD, et al. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 1998; 16:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/57\">",
"      Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19:3306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/58\">",
"      Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/59\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/60\">",
"      DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/61\">",
"      Vallo A, Rodriguez-Leyva F, Rodr&iacute;guez Soriano J. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr 2006; 95:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/62\">",
"      Chevrel G, Schott AM, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 2006; 21:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/63\">",
"      Stenson WF, Newberry R, Lorenz R, et al. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005; 165:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/64\">",
"      Armagan O, Uz T, Tascioglu F, et al. Serological screening for celiac disease in premenopausal women with idiopathic osteoporosis. Clin Rheumatol 2005; 24:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/65\">",
"      Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 159:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/66\">",
"      Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006; 74:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/67\">",
"      Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 2002; 9:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/68\">",
"      Gambacciani M, Cappagli B, Lazzarini V, et al. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas 2006; 54:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/35/42553/abstract/69\">",
"      Palomba S, Orio F Jr, Morelli M, et al. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab 2002; 87:4476.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2060 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-124.240.187.80-2DF51791C9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42553=[""].join("\n");
var outline_f41_35_42553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intensity of exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7269673\">",
"      - Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9986554\">",
"      High risk for ongoing bone loss or fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Osteogenesis imperfecta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Secondary causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2060|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/59/12220\" title=\"table 1\">",
"      Guidelines for BMD testing in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/47/13052\" title=\"table 2\">",
"      Secondary causes of osteoporosis in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/47/5884\" title=\"table 3\">",
"      Laboratory evaluation for premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/37/1627\" title=\"table 4\">",
"      Management of premenopausal osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37545?source=related_link\">",
"      Evaluation and management of aromatase inhibitor-induced bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26185?source=related_link\">",
"      Osteogenesis imperfecta: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=related_link\">",
"      Overview of the use of osteoclast inhibitors in early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_35_42554="Advanced case 1";
var content_f41_35_42554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1274px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Advanced case 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42554=[""].join("\n");
var outline_f41_35_42554=null;
var title_f41_35_42555="EUS FNA submucosal lesions";
var content_f41_35_42555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic characteristics of endoscopic ultrasound-guided fine-needle aspiration (EUS FNA) for gastrointestinal wall lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Accuracy (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giovannini, 1995",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gress, 1997",
"       </td>",
"       <td class=\"centered\">",
"        27",
"       </td>",
"       <td class=\"centered\">",
"        --",
"       </td>",
"       <td class=\"centered\">",
"        --",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wiersema, 1997",
"       </td>",
"       <td class=\"centered\">",
"        103",
"       </td>",
"       <td class=\"centered\">",
"        61",
"       </td>",
"       <td class=\"centered\">",
"        79",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Williams, 1999",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        38",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Norton ID, Wiersema MJ. Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography, Gress F, Bhattacharya I (Eds), Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42555=[""].join("\n");
var outline_f41_35_42555=null;
var title_f41_35_42556="US prehospital provider scope of practice";
var content_f41_35_42556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    United States responder and emergency medical technician scope of practice",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Provider (current designation)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Provider (future designation)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Scope of practice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        First responder",
"       </td>",
"       <td>",
"        Emergency medical responder (EMR)",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Ensure environment is safe to enter and provide care",
"         </li>",
"         <li>",
"          Gather initial history",
"         </li>",
"         <li>",
"          Appropriate physical examination",
"         </li>",
"         <li>",
"          Remove patient(s) from immediate danger",
"         </li>",
"         <li>",
"          Basic cardiopulmonary resuscitation",
"         </li>",
"         <li>",
"          Operate an automated external defibrillator",
"         </li>",
"         <li>",
"          Oxygen administration",
"         </li>",
"         <li>",
"          Insert oropharyngeal airway",
"         </li>",
"         <li>",
"          Suction airway",
"         </li>",
"         <li>",
"          Provide bag-mask ventilation",
"         </li>",
"         <li>",
"          Apply direct pressure for control of bleeding",
"         </li>",
"         <li>",
"          Administer unit dose auto-injectors (eg, epinephrine)",
"         </li>",
"         <li>",
"          Perform bandaging",
"         </li>",
"         <li>",
"          Provide manual C-spine and fracture stabilization",
"         </li>",
"         <li>",
"          Assist uncomplicated delivery of newborn",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency medical technician-Basic (EMT-B)",
"       </td>",
"       <td>",
"        Emergency medical technician (EMT)",
"       </td>",
"       <td>",
"        As for first responder and:",
"        <ul>",
"         <li>",
"          Obtain consent for or refusal of care",
"         </li>",
"         <li>",
"          Perform basic on-scene triage",
"         </li>",
"         <li>",
"          Access and extricate trapped victims",
"         </li>",
"         <li>",
"          Apply traction splint",
"         </li>",
"         <li>",
"          Perform spine immobilization (C-spine and backboard)",
"         </li>",
"         <li>",
"          Apply tourniquet",
"         </li>",
"         <li>",
"          Apply pneumatic antishock garment if indicated",
"         </li>",
"         <li>",
"          Irrigate eyes",
"         </li>",
"         <li>",
"          Provide basic burn management",
"         </li>",
"         <li>",
"          Perform basic poisoning management (administration of activated charcoal)",
"         </li>",
"         <li>",
"          Assist patient in taking their own prescribed medications (eg, nitroglycerin SL)",
"         </li>",
"         <li>",
"          Administer limited types of oral medications (eg, aspirin, glucose paste)",
"         </li>",
"         <li>",
"          Assist complicated delivery of newborn",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency medical technician-Intermediate (EMT-I)",
"       </td>",
"       <td>",
"        Advanced emergency medical technician (AEMT)",
"       </td>",
"       <td>",
"        As for first responder, EMT-B and:",
"        <ul>",
"         <li>",
"          Insert esophageal-tracheal or multi-lumen airway",
"         </li>",
"         <li>",
"          Suction already intubated patients",
"         </li>",
"         <li>",
"          Obtain peripheral IV access",
"         </li>",
"         <li>",
"          Perform IO access",
"         </li>",
"         <li>",
"          Administer IV fluids",
"         </li>",
"         <li>",
"          Administer limited medications (eg, nitroglycerine SL, IM or SC epinephrine, IV dextrose, IM or IV naloxone)",
"         </li>",
"         <li>",
"          Administer inhaled beta agonists",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     C-spine: cervical spine; SL: sublingual; IO: intraosseous; IV: intravenous; IM: intramuscular; SC: subcutaneous.",
"     <br/>",
"     * Proposed in United States document, EMS Education Agenda for the Future: A Systems Approach (www.nhtsa.gov/people/injury/ems/FinalEducationAgenda.pdf [Accessed on May 08, 2012]).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42556=[""].join("\n");
var outline_f41_35_42556=null;
var title_f41_35_42557="TNM stage Merkel";
var content_f41_35_42557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor (eg, nodal/metastatic presentation without associated primary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tis",
"       </td>",
"       <td colspan=\"3\">",
"        In situ primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td colspan=\"3\">",
"        Less than or equal to 2 cm maximum tumor dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td colspan=\"3\">",
"        Greater than 2 cm but not more than 5 cm maximum tumor dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Over 5 cm maximum tumor dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor invades bone, muscle, fascia, or cartilage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        cN0",
"       </td>",
"       <td colspan=\"3\">",
"        Nodes negative by clinical exam* (no pathologic node exam performed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pN0",
"       </td>",
"       <td colspan=\"3\">",
"        Nodes negative by pathologic exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        N1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis in regional lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Micrometastasis&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Macrometastasis&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N2",
"       </td>",
"       <td colspan=\"3\">",
"        In transit metastasis&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        M1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis beyond regional lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis to skin, subcutaneous tissues or distant lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis to lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis to all other visceral sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups&sect;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 0",
"       </td>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IA",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        pN0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IB",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        cN0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIA",
"       </td>",
"       <td>",
"        T2/T3",
"       </td>",
"       <td>",
"        pN0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIB",
"       </td>",
"       <td>",
"        T2/T3",
"       </td>",
"       <td>",
"        cN0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIC",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIA",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N1a",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIB",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        cN1/N1b/N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IV",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Clinical detection of nodal disease may be via inspection, palpation, and/or imaging.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Isolated tumor cells in a lymph node are classified as micrometastases (N1a) and the presence of isolated tumor cells recorded using the prognostic factor. Micrometastases are diagnosed after sentinel or elective lymphadenectomy.",
"      <br>",
"       &Delta; Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or needle biopsy.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        In transit metastasis: a tumor distinct from the primary lesion and located either between the primary lesion and the draining regional lymph nodes or distal to the primary lesion.",
"        <br>",
"         &sect; Patients with primary Merkel cell carcinoma with no evidence of regional or distant metastases (either clinically or pathologically) are divided into two stages: Stage I for primary tumors &le;2 cm in size and Stage II for primary tumors &gt;2 cm in size. Stages I and II are further divided into A and B substages based on method of nodal evaluation. Patients who have pathologically proven node negative disease (by microscopic evaluation of their draining lymph nodes) have improved survival (substaged as A) compared to those who are only evaluated clinically (substaged as B). Stage II has an additional substage (IIC) for tumors with extracutaneous invasion (T4) and negative node status regardless of whether the negative node status was established microscopically or clinically. Stage III is also divided into A and B categories for patients with microscopically positive and clinically occult nodes (IIIA) and macroscopic nodes (IIIB). There are no subgroups of Stage IV Merkel cell carcinoma.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42557=[""].join("\n");
var outline_f41_35_42557=null;
var title_f41_35_42558="Unequal z-plasty";
var content_f41_35_42558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Unequal Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42558=[""].join("\n");
var outline_f41_35_42558=null;
var title_f41_35_42559="Elevated right hemidiaphragm";
var content_f41_35_42559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Eventration of the diaphragm in a neonate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior and lateral views of the chest demonstrating an elevated right hemidiaphragm in a neonate. On the lateral view, the anterior and posterior diaphragmatic attachments are in the correct positions. With diaphragmatic paralysis, the elevated hemidiaphragm would be uniformly elevated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_35_42559=[""].join("\n");
var outline_f41_35_42559=null;
